We’re on a mission to improve and extend lives by learning from the experience of every person with cancer.
Who we are

What we do
At Flatiron, we believe learning from the experience of every person with cancer is an imperative—it is the key to accelerating research and continuing to improve the quality of care.
Our vision is to build a world where technology and science close the gap between care and research.


Our story
Flatiron Health is a healthtech company dedicated to improving cancer treatment and advancing research. As the pioneer in real-world evidence for oncology, we provide technology and services to support patient care and make every person’s story count. We partner with hundreds of cancer centers, 20+ top global developers of oncology therapeutics, and researchers and regulators around the world.
Founded in 2012, Flatiron became an independent affiliate of the Roche Group in 2018. Under the new leadership of CEO Carolyn Starrett in 2021, we’ve expanded our commitment to advance research and treatment for patients around the globe. Flatiron International subsidiaries in Japan, Germany and the United Kingdom will partner with hospitals and health networks in collaborations tailored to each market’s needs and legal, regulatory and compliance requirements.
Our team
We’re a diverse group of passionate, curious individuals from a wide range of backgrounds, working together to solve problems that matter.


Nick is responsible for leading the compliance and privacy teams who are responsible for ensuring that Flatiron Health maintains the highest level of integrity and ethical standards by conducting its business activities in accordance with applicable laws and regulations, while also advocating for the safe use and handling of patient information.
Nick joined Flatiron with fifteen years of legal, compliance, and privacy experience within the provider, tech, data, and life sciences spaces. Prior to joining Flatiron in December 2021, he held global roles at GSK, IQVIA, and IBM Watson Health, where his work was at the intersection of data, technology, AI, and privacy with a strong focus on de-identification methodologies and data transformation technologies.
Nick received a B.A. in Theology from Boston College and he received his J.D. from Loyola College of Law, New Orleans. He is licensed as an attorney in the state of Massachusetts and is a certified information privacy professional.


Rory Brecker serves as General Counsel at Flatiron Health, where she leads the Legal team, as well as supports strategic partnerships and M&A activity across the company.
Prior to joining Flatiron, she practiced as a corporate healthcare associate at DLA Piper. Her practice included representation of strategic buyers and sellers, equity fund sponsors, and healthcare providers in all facets of M&A, as well as on-going representation of equity fund portfolio companies, including general corporate governance and other day-to-day corporate and healthcare regulatory matters. Before DLA, Rory was the Ethics & Compliance Manager at Nicklaus Children’s Hospital, a nationally ranked pediatric hospital.
Rory earned her bachelor’s degree from University of Wisconsin-Madison and J.D. from University of Florida – Levin College of Law.


Alex leads a team that builds on Flatiron’s established leadership in real-world evidence with new technologies and services to better integrate research into everyday clinical care. Flatiron Clinical Research helps sponsors and research sites design better studies, broaden access to and representativeness of clinical trials, accelerate timelines, and reduce the operational burden usually associated with clinical research.
Alex joined Flatiron in 2016 with a decade of experience working with oncology-focused pharmaceutical and biotech companies to address a wide range of strategic and operational challenges.
Alex received a bachelor of science in biological engineering and a master of engineering in biomedical engineering from Cornell University.


Bruce is responsible for guiding our long term growth and operating performance across Flatiron, and scaling the enterprise capabilities, systems, and processes required to achieve our ambitions.
Prior to joining Flatiron, Bruce was Chief Legal Officer at Zocdoc and EVP of Business Development and General Counsel (GC) at Oscar Health, where he was integral to scaling operations and driving growth.
Bruce graduated from Harvard Law School and received his bachelor’s degree from Harvard University in Economics.


Nathan leads teams that develop strategic partnerships and projects to accelerate Flatiron’s growth and enhance product offerings, and he spearheads the company’s expansion beyond the United States.
Nathan joined Flatiron in 2020 with 20 years of pharmaceutical experience in oncology and neuroscience business development and commercial leadership in the United States, Canada, and China.
He previously was global head of healthcare ecosystems at Roche Pharmaceuticals, establishing personalized health care collaborations in 10+ countries, and also served as director of data and digital partnering.
Nathan received a bachelor of arts in economics, with minors in english literature and psychology, from DePauw University and an MBA from Stanford University.
He loves to travel with his wife and has visited more than 80 countries.


Javier Jimenez MD, MPH, is the Chief Medical Officer at Flatiron Health where he is responsible for defining and executing the company’s strategic vision for real-world evidence, providing thought leadership and guidance around novel clinical research methods, and partnering with clients and stakeholders across academia, life sciences and government agencies to further the use of real-world data. In this role, Javier works cross-functionally to drive the overall strategy and execution of Flatiron’s research business.
Prior to Flatiron, Javier led the Real World Evidence and Late Phase business at Syneos Health. During his time at Syneos Health, he grew the RWE function, integrating RWE solutions experts, data and analytics, innovation and RWE clinical operations, while driving the RWD and analytics and technology strategy.
He is an MD and Epidemiologist by training. Javier’s career includes building the RWE and Clinical Outcomes team at Sanofi and 15+ years leading Medical Evidence, Observational Research, Epidemiology, Regulatory, and HTA teams across the US and Europe at AstraZeneca. In this capacity, he gained his vast experience in Oncology including leading AstraZeneca’s collaboration with ASCO’s CancerLinQ.
Javier received his MD at Universidad de Alcalá in Madrid, Spain and completed his Master of Public Health from the National School of Public Health also in Madrid, Spain. Javier also completed enterprise leadership courses at both MIT Sloan School of Management, and London School of Business.


Jaime Lopez is the Chief Design & Marketing Officer at Flatiron Health. She has over 15 years of startup product, design and marketing experience with a passion for creative problem solving and building and mentoring teams.
In her role at Flatiron Health, Jaime uses her background to create and deliver high-quality experiences to oversee the company’s entire marketing and design suite.
Prior to joining Flatiron Health in 2016, Jaime led the design team at Opower, a startup working to address climate change, and worked for clients such as The Pan American Health Organization, Nestle, HP, Product (Red) and Neil Diamond.
She holds a Bachelor’s degree from the Art Center College of Design with a focus on Design for Social Impact. Her work has been recognized by Communication Arts Magazine, HOW International Design Annual Awards, Art Directors Club, Print Magazine and The Fast Company Innovation Awards.


Cat oversees the software engineering teams that build and deliver Flatiron’s real-world evidence (RWE) products and services, including our Enhanced Datamart, Spotlight, and prospective evidence products. She has been responsible for the RWE business line since its inception in 2014. In addition, for the past four years, Cat has been a key recruiting partner, more than doubling the software engineering team.
Prior to joining Flatiron in 2014, Cat was an early engineer at data-focused startups Mortar Data and Optum Humedica. She also acted in films including “Forever Mind.”
Cat has bachelors of science in mathematics and computer science and a master of engineering in computer science from the Massachusetts Institute of Technology.


Julia leads the teams responsible for the experience and growth of our network of oncology practices and our expansion into new markets.
Since joining Flatiron in 2015, Julia has built customer experience into a market differentiator, scaling high performing and customer-centric teams.
Previously, Julia worked in healthcare technology and consulting roles at ZocDoc, Bain & Co., Prophet, and Katzenbach.
Julia received a bachelor of arts in social studies and an MBA from Harvard University.


Stephanie leads the Real-World Evidence business unit, setting the strategy to drive long term growth and to accelerate Flatiron’s leadership in the way real-world oncology data is collected, combined and analyzed.
Steph joined Flatiron in 2022, with 20 years of experience leading businesses at the intersection of real-world patient data, technology, and analytics within the life sciences industry. Prior to Flatiron, she served as the General Manager of Life Sciences Data and Analytics at Veradigm, an analytics subsidiary of Allscripts.
Steph earned her bachelor’s degree at Widener University and is a candidate for her master’s in business administration at the Smeal College of Business at Penn State University.


Carolyn Starrett oversees Flatiron Health’s community oncology and research businesses and all corporate functions.
She previously led Flatiron’s community oncology business, and succeeded Co-Founder Nat Turner as CEO on April 16, 2021.
Prior to joining Flatiron in 2016, Carolyn spent 10 years in senior strategy, product, and operations roles at data and technology companies, and five years consulting with healthcare and technology companies at Boston Consulting Group.
Carolyn holds a BA in economics and literature from Brown University and an MBA from the Kellogg School of Management.


Prior to joining Flatiron, Ara was Chief People Officer at Cityblock Health. Ara also played a formative role scaling talent, culture, and employee experience at Audible.


Shane leads the commercial organization that develops partnerships with life sciences companies, advancing our customers’ research priorities through new approaches to evidence.
Shane has over a decade of experience in the oncology space. Prior to joining Flatiron in 2014, he partnered with leading oncology-focused biopharmaceutical companies to support their R&D and commercial strategies. Shane is a scientist by training, having completed research appointments in cancer biology at several academic institutions, including Harvard Medical School and the University of Notre Dame.
Shane holds a doctorate in genetics from the University of Cambridge, in England, where he studied as a Bill Gates Scholar. He completed his BS with honors in biochemistry at Queen’s University in Canada.


Ivy Altomare is a medical oncologist and hematologist who serves as a senior medical director at Flatiron Health, where she focuses on conducting outcomes research.
Prior to joining Flatiron in 2021, Ivy was an associate professor at Duke University and the assistant medical director of the Duke Cancer Network, where she practiced community oncology and hematology in underserved rural communities in North Carolina. She is an award-winning educator and maintains an oncology practice at Durham Veteran’s Hospital.
Ivy received her undergraduate degree from the University of Pennsylvania and an MD from Rutgers New Jersey Medical School. She completed her residency and oncology fellowship at the Icahn School of Medicine at Mount Sinai.


Emily Castellanos is a medical oncologist and hematologist who serves as a senior medical director at Flatiron Health, where she leverages her clinical and research expertise to develop innovative approaches to real-world evidence generation and inform product strategy. She has a special interest in integrated approaches to real-world data, such as clinico-genomics, clinico-claims, or imaging data, as well as novel approaches to real-world study design.
Prior to coming to Flatiron, she served on the faculty in the division of hematology/oncology at Vanderbilt University Medical Center. Emily also maintains a clinical practice specializing in breast malignancies at Fox Chase Cancer Center.
Emily earned her bachelor of science with distinction in biological sciences from Stanford University. She then received her MD from Vanderbilt University Medical Center, where she remained for her clinical training. She completed her residency in internal medicine, and after serving as chief resident she remained at Vanderbilt for her hematology/oncology fellowship and earned her MPH with a focus on health policy.


Cheryl Cho-Phan is a Medical Oncologist and serves as a Medical Director at Flatiron Health, where she applies her clinical expertise and research background to accelerate learning through the generation of real-world evidence, particularly in the area of clinicogenomics to improve patient care and outcomes.
Prior to joining Flatiron, Cheryl worked at Syapse as Director of Medical Oncology. Before Syapse, Cheryl was a Clinical Assistant Professor in the Department of Medicine, Division of Oncology at Stanford University where she was a clinical trial investigator focused on the care of patients with gastrointestinal malignancies.
Cheryl received her bachelor’s in environmental studies from Brown University and an MD from Georgetown University. She completed her internal medicine residency at Oregon Health Sciences University, and medical oncology fellowship at Stanford University.


Aaron Cohen is a medical oncologist, clinical informatician, and health outcomes researcher who serves as medical director at Flatiron Health. Aaron serves as the clinical lead for the machine learning team and focuses on the use of natural language processing and machine learning to facilitate cancer research and care.
Aaron has a faculty appointment at the NYU School of Medicine in the Department of Medicine and maintains a clinical practice at Bellevue Hospital, with a focus on solid organ malignancies. Prior to Flatiron, Aaron attended the University of Pennsylvania, where he completed his undergraduate and medical school training, as well as his master of science in Clinical Epidemiology. He completed his residency in internal medicine and fellowship in hematology and oncology at the Hospital of the University of Pennsylvania, where he served as chief fellow. He is board certified in internal medicine, medical oncology, and clinical informatics.


Majd Ghanim is a pediatric hematologist oncologist who serves as a medical director at Flatiron Health, where he applies his clinical knowledge and clinical trial expertise to support prospective real-world studies.
Prior to joining Flatiron Health, Majd was a medical director at AbbVie, leading clinical trials and drug development in the hematology oncology space.
Majd earned his MD from the University of Jordan and received his master of science in Clinical Research from the Medical University of South Carolina. He completed his pediatrics residency at Beaumont Hospital and pediatric hematology oncology fellowship at the Medical University of South Carolina.
Majd is board certified in pediatrics and pediatric hematology oncology.


James Hamrick leads a team of doctors, nurses, and informatics specialists who inform the development and applications of the Flatiron HC™ products and services relied upon by front-line clinicians in hundreds of cancer clinics across the United States.
James also maintains a clinical practice part-time in Atlanta. He joined Flatiron from Kaiser Permanente of Georgia in 2016, where he served as chief of medical oncology and hematology. Prior to that he practiced at Georgia Cancer Specialists. He is on the board of the Georgia Center for Oncology Research and Education, and previously served on the Kaiser Permanente National Inter-Regional Cancer Leadership Council and the KP National Cancer Chiefs Council.
James received his MD and an MPH in epidemiology from the University of North Carolina at Chapel Hill. He completed his residency and hematology/oncology fellowship at the University of California San Francisco.
James is board-certified in internal medicine, medical oncology, and hematology.


Neal J. Meropol, MD is a medical oncologist, clinical investigator and outcomes researcher who serves as Vice President of Research Oncology, and Scientific and Clinical Lead for Clinical Research at Flatiron Health. In this role, he provides leadership in leveraging Flatiron’s technology platforms to close the gap between research and clinical care.
Dr. Meropol’s research contributions span drug development and health services research, including evaluation of new agents, predictors of response and outcome, development of tools to overcome barriers to clinical trial participation, and assessment of the economic impact of care. His current focus is developing technologic innovations to enable clinical research to take place wherever care is delivered.
He is currently the co-chair of the NCI Streamlining Clinical Trials Working Group, and previously served as chair of the NCI Clinical Trials and Translational Research Advisory Committee (CTAC), and chair of the National Cancer Institute Gastrointestinal Cancer Steering Committee. Dr. Meropol completed a four-year term as an elected member of the American Society of Clinical Oncology (ASCO) Board of Directors, and currently serves on the ASCO Research Committee. He also served as a member of the National Academies of Science, Engineering and Medicine National Cancer Policy Forum. A committed educator, Dr. Meropol was faculty and chair of the AACR/ASCO Methods in Cancer Clinical Research Vail Workshop, and ASCO Leadership Development Program. He has authored more than 300 manuscripts, book chapters, and editorials related to cancer prevention, treatment, decision making and health economics.
Prior to joining Flatiron, he served as Professor and Chief of the Division of Hematology and Oncology at University Hospitals Cleveland Medical Center and Case Western Reserve University, and Associate Director for Clinical Research at the Case Comprehensive Cancer Center.
Dr. Meropol holds a bachelor’s degree from Princeton University in Philosophy, and MD from Vanderbilt University. He was a resident in Internal Medicine at Case Western Reserve University, and completed Hematology and Medical Oncology fellowships at the University of Pennsylvania. He spent a sabbatical at the Leonard Davis Institute of Health Economics at the Wharton School of the University of Pennsylvania.


Trevor Royce is a radiation oncologist, clinical informatician, and health outcomes/policy researcher who serves as medical director at Flatiron Health, where he focuses on clinical research and collaborations with academic partners that leverage real-world evidence to accelerate progress in cancer treatment and improve patient outcomes.
Trevor has a faculty appointment at the Wake Forest School of Medicine in the Department of Radiation Oncology and maintains a clinical practice at a Veterans Affairs Medical Center with a focus on genitourinary cancers. Prior to joining Flatiron, he held a clinic and tenure-track faculty position at the University of North Carolina at Chapel Hill School of Medicine. Trevor regularly publishes in leading medical journals, serves on editorial boards and national committees and lectures nationally.
Trevor received his undergraduate degree in biomedical engineering from the University of Virginia and an MD from the University of North Carolina. He completed a radiation oncology residency at the Harvard Radiation Oncology Program where he served as Chief Resident and earned an MPH from the Harvard School of Public Health.
We embody our values

Solve problems that matter
Identify and solve problems that drive our mission forward. Prioritize rigorously by focusing on work that moves the needle for our customers and patients.

Our commitment to diversity, equity, and inclusion
We strive to create an environment where varied perspectives work together to transform cancer care. We believe in elevating voices, celebrating differences, and cultivating belonging.

Be the next changemaker in cancer care
Our commitment to data confidentiality
Flatiron has established and maintains robust standards for the communication and protection of confidential information.
Transforming global oncology research and care
We’re accelerating cancer research and improving the quality of care globally, using real-world evidence to improve patient outcomes, inform policy, and advance research